Highest-materiality recent filing
Cadrenal Q2 net loss narrows to $3.3M; Phase 2 CAD-1005 cuts thrombotic events >25%
Q2 2026 net loss of $3.3M vs $3.7M in Q2 2025; R&D expenses $0.7M vs $1.1M; G&A $2.6M vs $2.7M.
Cadrenal Therapeutics launches partnering process for late-stage cardiac critical care assets
Portfolio aligned into three pillars: Pre-Operative Safety (frunexian), Orphan Regulatory Acceleration (tecarfarin), Post-Operative Shield (CAD-1005).
Cadrenal Therapeutics CMO James J. Ferguson III resigns effective July 31, 2026
CMO James J. Ferguson III resigned; effective July 31, 2026.
Cadrenal Therapeutics raises $3M in private placement; warrants add up to $5.8M
Gross proceeds of $3M from sale of 960,000 pre-funded warrants at $3.1249/unit.
Cadrenal to file for FDA Rare Pediatric Disease Designation for tecarfarin in Kawasaki
Plans to submit RPDD request to FDA for tecarfarin to treat pediatric Kawasaki disease patients with coronary artery aneurysms.
Phase 2 data showed >25% absolute reduction in thrombotic events when CAD-1005 added to standard anticoagulant therapy.
Cadrenal Therapeutics receives $2.5M gross proceeds from warrant exercise, issues new warrants
Existing warrant holder exercises 571,430 shares at reduced price of $4.50 per share, yielding $2.5M gross proceeds.
Cadrenal Therapeutics reports Q4 net loss of $3.0M, cash $4.0M; CAD-1005 FDA EOP2 meeting completed
Q4 2025 net loss $3.0M vs $4.2M YoY; R&D expenses $0.7M vs $1.5M; G&A $2.4M vs $2.7M.
Cadrenal Therapeutics Phase 2 HIT trial: primary endpoint missed, thrombotic events reduced >25%
Platelet count recovery (primary endpoint) did not differ between CAD-1005 and placebo arms.
Cadrenal Therapeutics acquires VLX-1005, a Phase 2 12-LOX inhibitor for HIT, from Veralox
Acquisition closed Dec 10, 2025; upfront cash $200K plus milestone payments up to $15M and 5% royalties on net sales.
Cadrenal Therapeutics Q3 2025 net loss $2.7M; advances tecarfarin and frunexian pipeline
Net loss of $2.7M for Q3 2025 vs $2.4M in Q3 2024; cash and equivalents $3.9M as of Sept 30.
Cadrenal Therapeutics acquires eXIthera's Factor XIa inhibitors for up to $15M in milestones
Acquires frunexian (Phase 2-ready IV FXIa) and EP-7327 (IND-ready oral FXIa) from eXIthera.
Cadrenal reports Q2 net loss $3.7M, cash $5.6M; plans tecarfarin trial in ESKD dialysis patients
Net loss of $3.7M for Q2 2025 versus $2.4M in Q2 2024; G&A increased to $2.7M from $1.2M.
Cadrenal to begin tecarfarin trial in ESKD patients transitioning to dialysis later this year
Trial includes ESKD patients with and without atrial fibrillation, enrollment planned to begin later this year.
Cadrenal Therapeutics Q1 net loss widens to $3.8M; cash at $7.3M; tecarfarin development advances
Net loss of $3.8M for Q1 2025 vs $1.7M in Q1 2024; R&D expense $1.7M (up from $0.6M), G&A $2.3M (up from $1.1M).
Net loss of $10.7M for FY2024 (vs $8.4M in 2023); G&A expenses nearly doubled to $6.8M.
Cadrenal Therapeutics signs collaboration with Abbott to support Phase 3 LVAD trial of tecarfarin
Abbott will share LVAD data from MOMENTUM 3 and ARIES HM3 trials for TECH-LVAD trial design.
Cadrenal appoints James J. Ferguson as CMO; Dr. Douglas Losordo departs
Dr. Ferguson, over 25 years cardiovascular experience, appointed Chief Medical Officer effective Feb 5, 2025.
Cadrenal Therapeutics Q3 2024 cash $11.3M, raises $9.8M from ATM and warrants
Q3 2024 operating expenses $2.5M including $0.3M non-cash; cash used in operations $2.2M.
Cadrenal raises $4.7M via warrant exercise; issues new warrants for additional shares
Exercised 285,715 existing warrants at reduced price of $16.50/share, generating ~$4.7M gross proceeds.
Cadrenal Therapeutics raises $5.1M via ATM facility, selling 391,243 shares at $13.15
Gross proceeds of $5.1M from sale of 391,243 shares at weighted avg price of $13.15/share.
Phase 3 trial planned for LVAD patients: 440 patients randomized 1:1 tecarfarin vs warfarin for 26 weeks.
Cadrenal Therapeutics effects 1-for-15 reverse stock split to meet Nasdaq $1 minimum bid price
Reverse stock split at 1-for-15 effective 12:01 a.m. ET on August 20, 2024; shares reduced from ~16 million to ~1.1 million.
Cadrenal Therapeutics Provides Q2 2024 Corporate Update and Financial Results
Collaborated with Abbott to advance tecarfarin for LVAD patients using HeartMate 3 device.
Cadrenal partners with Abbott for pivotal tecarfarin trial in LVAD patients
Cadrenal (CVKD) and Abbott (ABT) initiate collaborative effort for tecarfarin pivotal trial in recently implanted LVAD patients.
Cadrenal stockholders approve reverse split, share increase, and equity plan amendment
Approved reverse stock split at Board's discretion (1:2 to 1:20 ratio).
Cadrenal Therapeutics receives FDA Orphan Drug Designation for tecarfarin in VAD patients
FDA granted ODD for tecarfarin to prevent thromboembolism/thrombosis in patients with LVADs, RVADs, biventricular assist devices, and total artificial hearts.
Cadrenal Therapeutics still not in compliance with Nasdaq minimum bid price; requests extension
Received Nasdaq deficiency letter on Sept 6, 2023 for bid price below $1.00 for 30 consecutive business days.
Cadrenal Therapeutics Q3 update: expands tecarfarin to LVAD/APS, cash $9.1M
Expanded tecarfarin development beyond ESKD with AFib to include LVAD and APS, adding $1.5B annual U.S. market opportunity.
Cadrenal Therapeutics receives Nasdaq minimum bid price deficiency notice
Nasdaq notice on Sept 6, 2023, for bid price below $1.00 for 30 consecutive days.
On July 7, 2026, James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc. (the “Company”), advised the Board of Directors of the Company of his decision to resign from his position as Chief Medical Officer of the Company, effective July 31, 2026 (the “Separation Date”).
On May 28, 2026, Cadrenal Therapeutics, Inc. (the "Company") and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.
Effective immediately after Mr. Szot's termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.
On February 4, 2025, Cadrenal Therapeutics, Inc. (the “Company”) entered into an employment agreement with James J. Ferguson III (the “Employment Agreement”), effective as of February 5, 2025 (the “Effective Date”), to employ Dr. Ferguson as the Company’s Chief Medical Officer.
On February 4, 2025, the Company terminated its employment relationship with its Chief Medical Officer, Douglas Losordo, on a mutual amicable basis.
On February 6, 2024, Cadrenal Therapeutics, Inc. (the “Company”) entered into an offer letter agreement (the “Offer Letter”) with Jeffrey Cole describing the terms of his employment as the Company’s Chief Operating Officer.
appointed Robert Lisicki to serve as a Class II director of the Company
Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.
Steven Zelenkofske was appointed as a Class III director
John Murphy was appointed as a Class II director
Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.
Glynn Wilson was appointed as a Class I director
Max materiality 0.85 · Median 0.60 · Most common event other_material